Fintel reports that on November 2, 2023, Cantor Fitzgerald initiated coverage of Immatics N.V (NASDAQ:IMTX) with a Overweight recommendation.
Analyst Price Forecast Suggests 148.46% Upside
As of November 1, 2023, the average one-year price target for Immatics N.V is 19.38. The forecasts range from a low of 14.14 to a high of $26.25. The average price target represents an increase of 148.46% from its latest reported closing price of 7.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Immatics N.V is 43MM, a decrease of 49.16%. The projected annual non-GAAP EPS is -1.45.
What is the Fund Sentiment?
There are 105 funds or institutions reporting positions in Immatics N.V. This is an increase of 17 owner(s) or 19.32% in the last quarter. Average portfolio weight of all funds dedicated to IMTX is 0.24%, an increase of 24.21%. Total shares owned by institutions increased in the last three months by 19.51% to 44,787K shares. 
The put/call ratio of IMTX is 0.42, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 5,724K shares representing 6.91% ownership of the company. In it's prior filing, the firm reported owning 6,038K shares, representing a decrease of 5.48%. The firm increased its portfolio allocation in IMTX by 974.71% over the last quarter.
Baker Bros. Advisors holds 5,641K shares representing 6.81% ownership of the company. In it's prior filing, the firm reported owning 5,187K shares, representing an increase of 8.04%. The firm increased its portfolio allocation in IMTX by 93.46% over the last quarter.
Perceptive Advisors holds 3,492K shares representing 4.22% ownership of the company. No change in the last quarter.
Sofinnova Investments holds 3,041K shares representing 3.67% ownership of the company. In it's prior filing, the firm reported owning 3,133K shares, representing a decrease of 3.00%. The firm increased its portfolio allocation in IMTX by 66.10% over the last quarter.
Rock Springs Capital Management holds 2,536K shares representing 3.06% ownership of the company. In it's prior filing, the firm reported owning 2,514K shares, representing an increase of 0.88%. The firm increased its portfolio allocation in IMTX by 68.24% over the last quarter.
Immatics N.V Background Information
(This description is provided by the company.)
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
